Recursion Pharmaceuticals, Inc. — Earnings Quality Grade F
RXRX · Healthcare
Major red flags
Screening Summary
管理层信号
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
Insufficient data
Insufficient data
Revenue grew 27.0% but CFFO declined -3.5%
Small-cap context: Small-cap revenue/CFFO ratio is sensitive to growth-stage working-capital draws.
Expense Quality
No material inventory
CapEx growth -49.4% vs revenue 27.0%. Normal
SG&A/Gross Profit = 5346.3%, exceeds 70%
Gross margin swung -18.2pp (22.7% → 4.4%)
Cash Flow Quality
CFFO < Net Income for 3 consecutive years
Small-cap context: Small-cap CFFO/NI often diverges from working-capital swings, not necessarily manipulation.
FCF is negative ($-0.4B)
Accruals ratio = -18.5%. Low accruals
Cash $0.7B covers debt $0.1B
Balance Sheet Health
Goodwill+Intangibles $0.5B = 42% of equity
Interest coverage = -358.1x (<2x). Financial stress
Other assets 30.0% vs revenue 27.0%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions negative for 3 years
Small-cap context: A single acquisition on a small balance sheet can trip serial-acquirer logic.
Goodwill+Intangibles change -3% YoY. Normal
Manipulation Score
Insufficient data
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25